Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months
A likely approval for a biosimilar to Eli Lilly and Company’s Forsteo (teriparatide) in the European Union will add a ‘significant’ but ‘not a massive’ product to the portfolio of Biolexis, the products division of Strides Pharma Science Limited’s biologics arm Stelis Biopharma.
Sizing up the opportunity as a $800m one globally and about $200m in Europe, Strides’ managing director and executive chairperson Arun Kumar told analysts and investors on a call “starting from
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
